Indivior Changes Course: Revenue Guidance Update
Indivior PLC (NASDAQ: INDV) is currently facing a challenging market landscape, which has prompted the company to adjust its revenue expectations for the upcoming year. This decision follows the preliminary results reported for the third quarter, indicating a decline in revenue.
Understanding Indivior's Recent Revenue Results
Indivior anticipates third-quarter net revenue to fall within the range of $302 million to $309 million. This estimate surpasses the consensus figure of approximately $289.37 million, reflecting an unexpected uptick in the quarter's performance.
2024 Revenue Guidance Reevaluation
The company has revised its FY24 net revenue outlook, now estimating a range of $1.125 billion to $1.165 billion. This marks a decrease from its previous guidance of $1.15 billion to $1.215 billion and falls below market expectations of $1.185 billion.
Challenges for SUBLOCADE
A significant factor contributing to this adjustment is the reduced revenue forecast for SUBLOCADE, a treatment used for opioid use disorder (OUD). Indivior now predicts SUBLOCADE to generate between $187 million and $192 million in net revenue for the third quarter. For the full fiscal year, the revenue expectation has been lowered to between $725 million and $745 million, down from prior projections of $765 million to $805 million.
CEO's Insights on Market Dynamics
Mark Crossley, the CEO of Indivior, provided insights into the market dynamics impacting the company. He highlighted the swift adoption of a competing product to SUBLOCADE, coupled with fluctuations in funding timing among Criminal Justice System customers, as critical contributors to the revenue decline. Crossley expressed that these factors necessitate a downward revision in their FY 2024 guidance.
The Future Landscape for SUBLOCADE
Looking ahead, Indivior anticipates that SUBLOCADE volume growth may face ongoing pressure due to the initial uptake of competitors in the U.S. market. The presence of two long-acting injectable products is expected to complicate market conditions further.
Long-Term Prospects and Revenue Potential
Despite the current challenges, Indivior remains optimistic about SUBLOCADE's long-term potential, maintaining expectations that its peak net revenue could exceed $1.5 billion. However, the company no longer predicts that SUBLOCADE will achieve a run rate of $1 billion by the close of 2025.
Continuous Improvement and FDA Updates
Crossley emphasized Indivior's belief in SUBLOCADE's unique profile that addresses the complexities of OUD treatment. The company is also looking forward to potential label updates in February 2025, aimed at enhancing both patient and provider experiences, pending FDA approval.
Company's Broader Financial Projections
In addition to revenue guidance adjustments, Indivior has maintained its outlook for an adjusted gross margin in the low to mid-80% range. However, the adjusted operating profit guidance has been lowered significantly to between $260 million and $280 million, down from earlier estimates of $285 million to $320 million for 2024.
Market Reaction to Revenue Forecast Changes
As a result of these announcements, shares of INDV have experienced a notable decline, dropping 16.6% to $7.87 in premarket trading, underscoring the market's reaction to the revised revenue expectations.
Frequently Asked Questions
What caused Indivior to lower its revenue guidance?
Market pressures, increased competition, and fluctuations in funding among customers prompted Indivior to revise its revenue expectations.
How much is Indivior expecting from SUBLOCADE in the next fiscal year?
Indivior anticipates net revenue for SUBLOCADE to be between $725 million and $745 million for the next fiscal year.
What did the CEO say about the competition?
The CEO noted a rapid adoption of a competitive product, which has negatively impacted SUBLOCADE's revenue.
What is the outlook for SUBLOCADE's peak revenue?
Indivior still expects SUBLOCADE's peak revenue to exceed $1.5 billion despite current challenges.
What adjustments were made to the operating profit guidance?
The adjusted operating profit guidance has been lowered to $260 million - $280 million for 2024.
